FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated...

FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma - New indication offers earlier treatment options for patients - CAMBRIDGE, Mass. and OSAKA, Japan, June 20 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) today announced that the U.S. Food and Drug Administration (FDA) approved VELCADE for patients with previously untreated multiple myeloma (MM). The Company's co-development partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) also has filed a corresponding application with the European Medicines Evaluation Agency (EMEA). (Logo: http://www.newscom.com/cgi-bin/prnh/20080620/NEF058LOGO-a ) (Logo: http://www.newscom.com/cgi-bin/prnh/20080620/NEF058LOGO-b )... [read full story]